Quick Answer
Travere Therapeutics, Inc. reported Cash and Equivalents of $93.03 million for fiscal year 2025.
Travere Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $93.03M | +58.9% |
| 2024 | $58.53M | +0.6% |
| 2023 | $58.18M | -5.7% |
| 2022 | $61.69M | -62.8% |
| 2021 | $165.75M | +95.5% |
| 2020 | $84.77M | +35.8% |
| 2019 | $62.44M | -39.3% |
| 2018 | $102.87M | +3.5% |
| 2017 | $99.39M | +142.4% |
| 2016 | $41.00M | +8.5% |
| 2015 | $37.80M | +107.7% |
| 2014 | $18.20M | +203.6% |
| 2013 | $6.00M | +54418.2% |
| 2012 | $11.0K | +9.4% |
| 2011 | $10.1K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $110.93M | +204.7% | +47.6% |
| June 30, 2025 | $75.15M | +132.7% | +21.4% |
| March 31, 2025 | $61.90M | +43.1% | +5.7% |
| December 31, 2024 | $58.53M | +0.6% | +60.8% |
| September 30, 2024 | $36.41M | -74.8% | +12.8% |
| June 30, 2024 | $32.29M | -54.4% | -25.3% |
| March 31, 2024 | $43.25M | -73.2% | -25.7% |
| December 31, 2023 | $58.18M | -5.7% | -59.7% |
- Travere Therapeutics, Inc. showed an increase of +58.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Travere Therapeutics, Inc.’s cash and equivalents has grown by 925345.1% (from $10.1 thousand to $93.03 million).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: